Immugenia Inc.
- Biotech or pharma, therapeutic R&D
To enhance accessibility to CAR (Chimeric Antigen Receptor) therapy, Immugenia is advancing research to administer CAR therapy directly in vivo, thus bypassing the need for ex vivo cell modifications. This approach combines our proprietary promoter technology, which allows CAR expression to be selective to T and NK cells, with lentiviral particles specifically designed to target immune cells.
By engineering hematopoietic stem cells using proprietary synthetic promoters, the drug candidate is leveraging both T and NK cells to treat cancer and prevent relapses, potentially for life.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}